Navigation Links
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
Date:2/14/2013

CRANBURY, N.J., Feb. 14, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2012.  Palatin reported a net loss of $1.7 million, or $(0.02) per basic and diluted share, for the quarter ended December 31, 2012, compared to a net loss of $2.6 million, or $(0.08) per basic and diluted share, for the same period in 2011. 

The decrease in net loss for the quarter ended December 31, 2012, compared to the same period last fiscal year, is primarily attributable to an increase in net proceeds from the sale of New Jersey state net operating loss carryforwards, which resulted in the recognition of $1.8 million and $1.1 million, respectively, in tax benefits for the three months ended December 31, 2012 and 2011, and secondarily to a decrease in operating expenses for the periods presented.

REVENUE
Revenues, which consisted of contract revenue pursuant to the collaboration agreement with AstraZeneca, were $6,555 for the quarter ended December 31, 2012 compared to $11,492 for the quarter ended December 31, 2011.

COSTS AND EXPENSES
Total operating expenses for the quarter ended December 31, 2012 were $3.4 million compared to $3.7 million for the comparable quarter of 2011.  The decrease in operating expenses for the quarter was primarily due to lower costs related to Palatin's Phase 2B clinical trial with bremelanotide for Female Sexual Dysfunction (FSD), which Palatin reported positive top-line results on November 8, 2012.

CASH POSITION
Palatin's cash and cash equivalents were $32.9 million as of December 31, 2012, compared to $3.8 million at June 30, 2012, with current liabilities of $2.0 million as of December 31, 2012 compared to $3.5 million as of June 30, 2012
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Angeles, CA (PRWEB) July 22, 2014 ... test solutions with the debut of its fluorescent ... of Clinical Chemistry (AACC) meeting in Chicago, July ... or bench top versions, the HRDR-300 is a ... pending technology to analyze fluorescent lateral flow immunoassays ...
(Date:7/21/2014)... July 21, 2014 Lawrence ... Investment Board (WIB) and Las Positas College (LPC) ... technical education and hands-on training for veterans, officials ... Program at Las Positas is designed to ... for engineering technician careers, and establishes a pipeline ...
(Date:7/21/2014)... PHILADELPHIA , July 21, 2014  Mike ... closing of $1.6 million in Series Seed B ... and chemical sensors for the life science, defense, ... Trimaran Capital Partners led the round and was ... 36 Angels.  Said Patterson , "This round ...
(Date:7/19/2014)... 20, 2014 United States Non-Vascular ... GlobalDatas new report, "United States Non-Vascular Stents Market ... the United States Non-Vascular Stents market. The report ... (in units) and average prices (in US dollars) ... Stents and Metal Biliary Stents (Metal Non-Covered Biliary ...
Breaking Biology Technology:Holomic to Debut HRDR-300 Fluorescent Immunoassay Reader at the AACC 2014 2Engineering Program Established for Veterans 2Engineering Program Established for Veterans 3Global Graphene Manufacturing Leader, Graphene Frontiers, Receives Series Seed B Funding To Assure Production Of The Next Generation Of Biological And Chemical Sensor Technology 2United States Non-Vascular Stents Market Outlook to 2020 | Researchmoz 2United States Non-Vascular Stents Market Outlook to 2020 | Researchmoz 3United States Non-Vascular Stents Market Outlook to 2020 | Researchmoz 4
... 2011 /PRNewswire-Asia/ -- China-Biotics, Inc. (NASDAQ GS: ... developer, manufacturer, and distributor of probiotics products in China, ... common stock at approximately 3:35 PM EDT on Wednesday, ... an extension of time to file with the Securities ...
... 16, 2011 Chiltern International Limited (Chiltern), a ... financial investment in Endpoint Clinical, Inc. (endpoint) further ... in April 2009. Glenn ... increase our investment in endpoint reflects our aligned ...
... 2011 , New Generation of the Ziehm ... Ziehm Imaging has launched a new generation of the ... cooling,system which allows it to be used over an almost ... for hybrid ORs.,Thanks to its mobility and significantly lower investment ...
Cached Biology Technology:China-Biotics Provides Update 2China-Biotics Provides Update 3Chiltern Announces Additional Investment in Endpoint 2SVS 2011: Ziehm Imaging Presents Latest Mobile C-armTechnology for Intraoperative use 2
(Date:7/22/2014)... The darker side of meerkats which sees them prevent ... explained in a new study. , Research into the desert ... pair and many adult helpers shows that the alpha ... breed. , The study shows how this way of life, ... can prove effective despite its sinister side. , Dominant ...
(Date:7/22/2014)... the the genus of planthopper known as Conosimus, which ... recently discovered in the southern part of the Iberian ... of it appears in the open-access Journal of ... new species, Conosimus baenai , has been named ... to the taxonomy of Iberian Hemiptera. , Conosimus ...
(Date:7/21/2014)... Jocelyn Millar , a professor of entomology ... Chemistry at the University of California, Riverside, has ... the International Society of Chemical Ecology ( ISCE ). ... Medal is the society,s highest honor. It is ... to chemical ecology, the study of chemicals that mediate ...
Breaking Biology News(10 mins):UC Riverside entomologist receives international honor for chemical ecology contributions 2
... French and Spanish . Researchers from ... Council (CSIC) and the University of Aveiro (Portugal) have studied ... previous step for the artificial reproduction of this material in ... applications such as the regeneration of human bones. This ...
... Advancement of Science (AAAS) has named Kenneth R. Miller, ... Cell Biology and Biochemistry at Brown University as winner ... Science and Technology. Miller was cited for "his ... He will receive the award during a 14 February ...
... rangelands of Iran have one of the world,s longest history ... and knowledge of the soil that has produced centuries of ... population of humans and livestock in the region has taken ... the soil is rapidly degrading. With the land overly stressed ...
Cached Biology News:A research work on molluscs nacre opens new doors for its possible use in biomedicine 2Biologist receives the 2008 AAAS Public Understanding of Science and Technology Award 2Preventing rangeland erosion: Developing better management practices in Iran 2
The imaging screen-K (Kodak), tritium, is a 20 x 25 cm storage phosphor screen that is used for the quantitation and imaging of 32P, 33P, 35S, 14C, and 3H....
The filter 695RDF55 Reflect 635 for the Molecular Imager FX is a band pass filter for Cy5 and Alexa Fluor 635 dyes....
The filter 605DF50 for the Molecular Imager FX is a band pass filter for ethidium bromide, SYPRO Red, SYPRO Ruby, Alexa Fluor 532 and 546, and Cy3 dyes when using the 635 nm laser....
... tube gel cell is a stand-alone apparatus ... electrophoresis applications. The upper buffer chamber can ... cm long for isoelectric focusing (IEF) applications. ... and cooling core, lower buffer chamber, lid ...
Biology Products: